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Mitochondria are crucial bioenergetics powerhouses and biosynthetic hubs within cells,
which can generate and sequester toxic reactive oxygen species (ROS) in response to
oxidative stress. Oxidative stress-stimulated ROS production results in ATP depletion
and the opening of mitochondrial permeability transition pores, leading to mitochondria
dysfunction and cellular apoptosis. Mitochondrial loss of function is also a key driver in
the acquisition of a senescence-associated secretory phenotype that drives senescent
cells into a pro-inflammatory state. Maintaining mitochondrial homeostasis is crucial for
retaining the contractile phenotype of the vascular smooth muscle cells (VSMCs), the
most prominent cells of the vasculature. Loss of this contractile phenotype is associated
with the loss of mitochondrial function and a metabolic shift to glycolysis. Emerging
evidence suggests that mitochondrial dysfunction may play a direct role in vascular
calcification and the underlying pathologies including (1) impairment of mitochondrial
function by mineral dysregulation i.e., calcium and phosphate overload in patients with
end-stage renal disease and (2) presence of increased ROS in patients with calcific
aortic valve disease, atherosclerosis, type-II diabetes and chronic kidney disease. In
this review, we discuss the cause and consequence of mitochondrial dysfunction in
vascular calcification and underlying pathologies; the role of autophagy and mitophagy
pathways in preventing mitochondrial dysfunction during vascular calcification and finally
we discuss mitochondrial ROS, DRP1, and HIF-1 as potential novel markers and
therapeutic targets for maintaining mitochondrial homeostasis in vascular calcification.
Keywords: mitochondria, VSMCs, calcification, mitophagy, oxidative phoshorylation
INTRODUCTION
The process of calcification takes place due to the precipitation of insoluble salts of calcium
carbonate and calcium phosphate. In soft tissues, three different types of calcifications are
present, dystrophic (occurs in damaged or necrotic tissue), metastatic (hypercalcemia or
hyperphosphatemia in blood) and calcinosis (deposition of calcium in the skin, subcutaneous
tissue, muscles, and visceral organs) (Black and Kanat, 1985; Booth et al., 2017). Vascular
calcification is the most frequent type of soft tissue calcification whereby calcium (Ca) and
phosphate (Pi) accumulates in blood vessels and cardiac valves. Vascular calcification is a significant
risk factor for cardiovascular morbidity and mortality in patients with end stage renal disease
(ESRD), diabetes and atherosclerosis. Currently, there is no pharmaceutical strategy to prevent this
pathological process.
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Vascular calcification can be classified into three main
types based on location: intimal arterial (associated with
atherosclerosis), medial arterial (associated with ESRD and
diabetes), and aortic valve (associated with calcific aortic
valve disease) (Lanzer et al., 2014). The cell types that drive
vascular calcification include vascular smooth muscle cells
(VSMCs), endothelial cells, calcifying vascular cells, pericytes
and valve interstitial cells. These cells types contribute to
the formation of calcified nodules and undergo osteogenic
phenotype switching. This phenotype switching can lead to either
osteoblast or chondrocyte-like differentiation (Hortells et al.,
2018). Indeed, both of these cell types are present within small
areas of calcification in the innominate arteries in the advanced
atherosclerotic lesions of atherosclerosis-prone apolipoprotein
E-deficient (ApoE−/−) mice (Rosenfeld et al., 2000; Davaine
et al., 2016). However, advanced atherosclerotic plaques in
human patients do not contain osteoblast or chondrocyte-like
cells. Instead, they are rich in apoptotic smooth muscle cells,
macrophages and cells associated with inflammation (Herisson
et al., 2011; Jinnouchi et al., 2020).
Vascular calcification is also associated with apoptosis
(Ewence et al., 2008), matrix vesicle release (Chen et al., 2018),
and subsequent hydroxyapatite [Ca10(PO4)6OH2] deposition
within tissues (Lee et al., 2012). The source of hydroxyapatite
nucleation has yet to be fully elucidated with three key origins
discussed in the literature: (1) Nucleation of hydroxyapatite
within the lumen of matrix vesicles and subsequent release into
extracellular matrix (Buchet et al., 2013). (2) Hydroxyapatite
nucleation within collagen fibrils (Weiner and Traub, 1986;
Landis et al., 1996) and (3) Release of mitochondrial-
derived vesicles to the extracellular space from Ca-overloaded
mitochondria (Boonrungsiman et al., 2012). This process of
hydroxyapatite deposition within the collagenous matrix of
vascular cells likely shares important biological features with the
process of bone formation (Doherty et al., 2003). While majority
of the hydroxyapatite originates as calcium phosphate (Bertazzo
et al., 2013), a small proportion of it is made up of calcium
carbonate, particularly in the human atherosclerotic calcified
plaques (Schmid et al., 1980). A group of isoenzymes called
carbonic anhydrases facilitates calcium carbonate deposition by
reversible conversion of carbon dioxide into bicarbonate (Adeva-
Andany et al., 2015). Furthermore, in addition to hydroxyapatite,
other sources of arterial calcification have also been reported,
like carbonate-rich calcium phosphate dense granules in collagen
matrix of calvarial osteoblasts (Nitiputri et al., 2016) and
whitlockite, a magnesium-containing crystal [(Ca, Mg)3(PO4)2]
observed in a mouse model of uremic arterial calcification
(Verberckmoes et al., 2007; Schlieper et al., 2010).
Key molecular determinants of vascular calcification have
been identified in health, disease, and pathological ectopic
Abbreviations: VSMCs, Vascular smooth muscle cells; ROS, Reactive oxygen
species; ATP, Adenosine triphosphate; Ca, calcium; Pi, phosphate; CKD, Chronic
kidney disease; ESRD, end stage renal disease; TCA, Tricarboxylic acid cycle;
TNAP, tissue-non-specific alkaline phosphatase; Runx2, runt-related transcription
factor 2; PPi, inorganic pyrophosphate; Drp1, dynamin-related protein 1; HIF-
1, hypoxia-inducible factor-1; AGEs, Advanced glycation end products; COMP,
Cartilage oligomeric matrix protein.
calcification (Giachelli, 1999). These include positive regulators
including, msh homeobox-2 like Msx2 (Zhou et al., 2013;
Andrade et al., 2017), runt-related transcription factor 2
(Runx2) (Speer et al., 2010), osteogenic morphogen like bone
morphogenetic protein-2 (Bmp-2) (Hruska et al., 2005), the
phosphate transporter PiT-1 (Li and Giachelli, 2007), and
the release of matrix vesicles (Bakhshian Nik et al., 2017).
Additionally, local enzymes including tissue-non-specific
alkaline phosphatase (TNAP) and phosphate-regulating
endopeptidase homolog X-linked (PHEX) are able to degrade
calcification inhibitors such as inorganic pyrophosphate (PPi)
and osteopontin (Quarles, 2003; Murshed and McKee, 2010;
Barros et al., 2013). Failure of this enzyme-substrate relationship
can lead to an accumulation or degradation of these key
inhibitors of calcification (Reznikov et al., 2020). Furthermore,
ankylosis homolog (ANKH) protein and the enzyme ecto-
nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1)
inhibit VSMC calcification through enhancing extracellular
PPi levels (Ho et al., 2000; Mackenzie et al., 2012; Back et al.,
2018; Roberts et al., 2020). The mechanisms through which
PPi inhibits vascular calcification include direct binding to
hydroxyapatite; increased levels of osteopontin induced via the
Erk1/2 and p38 MAPK signaling pathways, and inhibition of
TNAP activity (Addison et al., 2007). Moreover, cells expressing
ankylosis homolog (ANKH) release PPi and citrate (Ca chelator)
along with other tricarboxylic acid cycle (TCA) intermediates
including succinate andmalate (Hu et al., 2010; Szeri et al., 2019).
Interestingly, citrate treatment attenuates vascular calcification
(Yao et al., 2018) in a chronic renal failure rat model and reduces
high Pi-induced vascular calcification (Ciceri et al., 2016; Ou
et al., 2017; Yao et al., 2018). Furthermore, Matrix Gla protein
(MGP) binds to Ca and hydroxyapatite to function as a potent
inhibitor of vascular calcification (Hauschka et al., 1989; Luo
et al., 1997).
Given that vascular calcification is mainly driven by
mineral (Ca and Pi) overload and mitochondria are the
key regulators of intracellular Ca and Pi levels (Pozzan and
Rizzuto, 2000; Pozzan et al., 2000; Rizzuto et al., 2000), their
physiology and metabolic function is likely to be effected by
this pathological process. It has been demonstrated that an
uncontrolled increase in cytoplasmic Ca leads to significant
Ca overload within the mitochondria relative to the cytoplasm
(Rizzuto et al., 1993).VSMCs containing calcified mitochondria
have been reported as early as 1976 (Kim, 1976). Moreover,
VSMCs in healthy vessels show calcified mitochondria when
exposed to high Ca and Pi concentrations in vitro (Shroff
et al., 2010). Besides, swollen mitochondria enriched with
calcific nodules are a feature of a skeletal muscle injury
model of dystrophic calcification in mice (Zhao et al., 2009).
Additionally, mitochondrial dysfunction, oxidative stress, altered
mitochondrial metabolism and mtDNA damage are reported
in common diseases associated with vascular calcification
including ESRD (Gamboa et al., 2016; Roshanravan et al.,
2016), atherosclerosis (Madamanchi and Runge, 2007) and
type 2 diabetes (Nishikawa et al., 2000). Thus, mitochondria
offer a novel potential therapeutic target for inhibiting vascular
calcification. However, the mechanisms through which Ca and Pi
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overload impact specific mitochondrial components have yet to
be determined.
In this review, we discuss the role of mitochondria in
maintaining VSMC function, highlight important mechanisms
underpinning the cause and consequence of mitochondrial
dysfunction in vascular calcification and consider key
mitochondrial markers as targets for developing future
therapeutic strategies for the prevention of vascular calcification.
ROLE OF MITOCHONDRIA IN VSMC
FUNCTION
VSMCs within blood vessels require high concentrations of
intracellular Ca to maintain their contractile phenotype. This
influx of Ca takes place via voltage-activated L-type Ca
channels on the plasma membrane. Blocking Ca channels with
therapeutics such as verapamil and nifedipine (Ca channel
antagonist) reduces calcification both in VSMCs in vitro and
in patients with coronary calcification (Motro and Shemesh,
2001; Chen et al., 2010). Importantly, mitochondrial oxidative
metabolism is the key source of energy for VSMC contraction
(Paul, 1983).
VSMCs are the most abundant cells of the tunica media in
the vessel wall. Their pivotal role is to maintain vessel structure
and function. VSMCs in the vessel wall are often exposed
to blood pressure variability, particularly in disease settings
e.g., increased blood pressure variability during hypertension
(Parati, 2005). Recently, it has been shown that maintenance of
physiological blood pressure is required for preserving optimal
mitochondrial structure and function in VSMCs (Bartolak-Suki
and Suki, 2020). Any fluctuation in blood pressure variability
can alter ATP production, increase ROS generation and disturb
the mitochondrial network within VSMCs. Mitochondrial fission
and fusion proteins including mitofusins (MFN), mitochondrial
dynamin like GTPase (OPA1) and dynamin-related protein 1
(DRP1) regulate this mitochondrial reorganization during blood
pressure variability (Bartolak-Suki and Suki, 2020).
Additionally, VSMCs maintain a contractile phenotype under
physiological conditions, which facilitates blood flow through
the arteries. However, under biological stress or injury, the cells
differentiate into an osteogenic phenotype with an acquired
ability to proliferate, migrate and synthesize extracellular matrix
vesicles. These differentiated VSMCs migrate into the intima
layer of the vessel wall and can induce arterial stiffening (Lacolley
et al., 2017). This acquired ability of VSMCs to proliferate is
regulated by mitochondrial outer membrane proteins such as
mitofusin-2 (Mfn-2) (Li et al., 2015). Mitofusin-2 is required for
mitochondrial fusion (Santel and Fuller, 2001; Chen et al., 2003)
and is a primary determinant of oxidative stress-induced VSMC
apoptosis (Guo et al., 2007). Increased expression of Mitofusin-2
in VSMCs induces apoptosis through upregulated mitochondrial
bcl-2-associated X protein expression, increased Bax/Bcl-2 ratio,
cytochrome c release and activation of caspase-9 and caspase-3
(Guo et al., 2007).
Glycoprotein cartilage oligomeric matrix protein (COMP)
has a crucial role in maintaining mitochondrial homeostasis in
VSMCs. COMP is present both in the extracellular matrix
and in the cytoplasm where it binds to mitochondria.
Mitochondrial transplantation experiments in VSMCs suggest
that mitochondrial COMP regulates the contractile phenotype
of VSMCs (Jia et al., 2018). In VSMCS, COMP deficiency leads
to decreased mitochondrial membrane potential, defective
oxidative phosphorylation and significant mitochondrial
fragmentation/fission (Jia et al., 2018). COMP also interacts
with prohibitin 2, a mitochondrial inner membrane protein,
to maintain mitochondrial homeostasis. Prohibitin 2 plays a
key role in maintaining mitochondrial genome stability and
mitochondrial respiratory chain complex assembly (Bogenhagen
et al., 2003; Strub et al., 2011). Blocking the COMP-prohibitin2
interaction results in a marked reduction in mitochondrial
respiration, ATP production and the membrane potential, along
with increased VSMC differentiation (Jia et al., 2018). Together
these data illustrate the crucial role of mitochondria in the




Themechanisms underlying mitochondrial dysfunctional during
vascular calcification have yet to be elucidated. Indeed, current
literature suggests mitochondrial dysfunction as both a cause
and consequence of vascular calcification, as discussed below
(Figure 1).
Mitochondrial Dysfunction as a Cause of
Vascular Calcification
Vascular calcification is associated with cardiovascular diseases,
metabolic disorders hereditary conditions and renal dysfunction.
Vascular calcification is also induced by advanced glycation
end products (AGEs) and oxidative stress caused by ROS,
which are by-products of aerobic metabolism (Nowotny et al.,
2015; Zhu et al., 2018). Excessive ROS production causes
oxidative stress, which is heavily implicated in the initiation
and progression of vascular calcification, notably during the
osteogenic transdifferentiation of VSMCs. Here we discuss
the role of mitochondrial dysfunction as a cause of vascular
calcification in different calcification pathologies and the key
mechanisms potentially driving the calcification process.
Calcific Aortic Valve Disease
Calcific aortic valve disease starts with fibrotic thickening
followed by extensive calcification of valve leaflets. This leads
aortic stenosis and subsequent obstruction of left ventricular
outflow. Currently, aortic valve replacement by surgery is the
only available treatment for degenerative aortic stenosis.
Recent studies have revealed key evidence for a role of
mitochondrial dysfunction in the onset and advancement of
calcific aortic valve disease. Mitochondrial (mt) DNA haplogroup
analysis in a cohort of aortic stenosis patients has revealed an
increased presence of haplogroup H, suggesting haplogroup H as
a risk factor in developing aortic stenosis (Serrano-Teruel et al.,
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FIGURE 1 | Mitochondrial dysfunction as a cause or consequence of vascular calcification. Increased ROS generation and mineral dysregulation via damaged
mitochondrial electron transport chain (ETC) complexes are the likely key cause and consequence of mitochondrial dysfunction observed during vascular calcification.
(A) Calcium released from the hydroxyapatite crystals from the extracellular matrix can enter the cytoplasm via endosomes and make its way to the mitochondrial
matrix causing calcium (Ca) and phosphate (Pi) overload. This calcium and phosphate overload can damage the electron transport chain complexes and generate
ROS. (B) AGEs are glycotoxins which are elevated in diabetes. AGEs and the receptor for AGEs (RAGE) generate ROS from mitochondria and play a significant role in
accelerating the vascular calcification process by enhanced synthesis of extracellular matrix components. Furthermore, ROS production is enhanced in aging vascular
cells. (C) Enhanced ROS leads to vascular stiffening, vascular calcification, VSMC transition to osteoblast or chondrocyte-like cells and the metabolic switching from
oxidative phosphorylation to glycolysis. All these pathways are commonn denominators in pathologies including calcific aortic valve disease, atherosclerosis, type-II
diabetes, CKD, and ESRD.
2019). Indeed, mitochondrial haplogroup H is an established
risk factor for diseases including ischemic cardiomyopathy
and idiopathic dilated cardiomyopathy and is associated with
increased oxygen consumption and electron transport chain-
coupled ROS release (Fernandez-Caggiano et al., 2012, 2013).
Interestingly, increased accumulation of ROS in the form
of hydrogen peroxide (H2O2) is reported in human stenotic
aortic valves (Miller et al., 2008) and is implicated in the
progression of calcific aortic valve disease (Liberman et al.,
2008). Inversely, treating VSMCs with non-toxic concentrations
of hydrogen peroxide (H2O2) induces calcification with a
concomitant increase in osteogenic markers including TNAP,
collagen type I alpha1 (Col Iα1), Runx2 and osteocalcin (Byon
et al., 2008). However, shRNA -mediated silencing of Runx2
abrogates (H2O2) induced VSMC calcification, suggesting a
pivotal role for Runx2 in regulating oxidative stress-mediated
vascular calcification (Byon et al., 2008).
Importantly, a metabolic shift from fatty acid to glucose
utilization is seen in patients with aortic stenosis. Cardiac biopsy
samples taken from these patients during valve replacement
surgery show a decrease in expression of proteins involved in
fatty acid transport, β-oxidation, the TCA cycle and oxidative
phosphorylation, with a concomitant upregulation of glycolysis
mediators including GLUT1 and 4 proteins (Heather et al., 2011).
Atherosclerosis
Atherosclerosis is a major cause of stroke, myocardial infarction
and angina, whereby arteries become clogged with plaques rich in
fat, cholesterol and Ca (Ross, 1999; Abedin et al., 2004). Vascular
calcification, endothelial dysfunction, intimal thickening and
inflammation are the main features of atherosclerosis (Abedin
et al., 2004; Spagnoli et al., 2007; Tesauro et al., 2017).
Mitochondrial dysfunction in terms of mtDNA damage,
increased mitochondrial ROS production and dysfunctional
oxidative phosphorylation are present in both human and mouse
models of atherosclerosis (Ballinger et al., 2002). Mitochondrial
dysfunction-induced apoptosis can lead to plaque rupture thus
accelerating atherosclerotic lesion formation (Madamanchi and
Runge, 2007).
Recent clinical studies have reported increased mtDNA
damage in the peripheral blood mononuclear cells from
human atherosclerotic patients (Fetterman et al., 2016). The
underpinning role of mtDNA damage in atherosclerosis has been
interrogated in polymerase-γ proof reading deficient ApoE−/−
mice (polG−/−/ApoE−/−) (Yu et al., 2013). These mice display
defective exonuclease activity of mtDNA polymerase and thus
accumulate mtDNA mutations and deletions, leading to mtDNA
damage (Trifunovic et al., 2004). This study revealed that
mtDNA damage fuels atherosclerosis and generates higher-risk
plaques. VSMCs from polG−/−/ApoE−/− mice exhibited reduced
ATP, reduced proliferation and increased apoptosis and early
senescence. Furthermore, monocytes from polG−/−/ApoE−/−
mice showed increased release of interleukin-1β and tumor
necrosis factor-α, indicating a pro-inflammatory phenotype.
Future studies investigating the vascular calcification phenotype
of polG−/−/ApoE−/− mice would be of great interest.
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COMP, which has a role in maintaining VSMC
mitochondrial homeostasis, prevents VSMC osteochondrogenic
transdifferentiation by directly binding to BMP-2 (Du et al.,
2011). Calcifying VSMCs and arteries show reduced expression
of COMP. Over-expression of COMP ameliorates vascular
calcification both in vivo and in vitro (Du et al., 2011).
Conversely, ApoE−/− mice lacking COMP show an increase
in size of atherosclerotic lesions in the brachiocephalic artery
(Bond et al., 2014). Together these studies highlight COMP as an
important regulator of vascular calcification and a novel target in
the prevention of atherosclerosis.
Extensively calcified aortic tissues and advanced
atherosclerotic plaques in patients show an increased expression
of mitochondrial carbonic anhydrases (Yuan et al., 2019).
Mitochondrial carbonic anhydrases generate ROS via the
generation of mitochondrial bicarbonate necessary for oxidative
glycolysis. Carbonic anhydrases catalyze the conversion of
CO2 to HCO3
− and H+ thus increasing cellular acidification
(Swietach et al., 2010). This acidification can also precipitate
calcium from calcium carbonate, a potential; driver of aortic
calcification in CKD patients on calcium carbonate supplements
(Phan et al., 2008). Blocking the activity of mitochondrial
carbonic anhydrases with acetazolamide alleviates calcification
in VSMCs along with the inhibition of inflammatory cytokines
associated with atherosclerosis (Yuan et al., 2019). Acetazolamide
exerts its effects through the prevention of mitochondrial
membrane depolarization and hydrogen peroxide (H2O2)
generation, thus reducing ROS (Yuan et al., 2019).
Type-II Diabetes
In type-II diabetic patients, medial calcification is a strong
independent predictor of cardiovascular mortality. Compared
with non-diabetic subjects, patients with diabetes show increased
vascular calcification and upregulation of bone-related proteins,
such as osteopontin, type I collagen, bone morphogenetic
protein-2 (BMP-2) and TNAP in the medial layer of the vessels
(Yahagi et al., 2017). Hyperglycemia, hyperlipidemia and insulin
resistance (the hallmarks of diabetes), play an active role in
the progression of vascular calcification. Hyperglycemia induces
vascular calcification through ROS and superoxide production,
either from mitochondria or from alternative sources, such
as NADPH oxidase (Nishikawa et al., 2000). Oxidative stress
is an important driver of atherosclerotic calcification in
diabetes in conjunction with additional factors including
endothelial dysfunction, alterations in mineral metabolism,
increased inflammatory cytokine production and formation of
osteoprogenitor cells. Furthermore, the generation of advanced
glycation end products (AGEs) is accelerated in diabetic patients,
leading to the subsequent enhancement of vascular calcification
through receptor of AGEs (RAGE) (Wei et al., 2013). The role of
AGEs in mitochondrial dysfunction is discussed in detail below.
Hutchinson-Gilford Progeria Syndrome
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare
premature aging disorder. A recent study investigated the
mechanisms underpinning excessive vascular calcification in
HGPS patients (Villa-Bellosta et al., 2013). Typically, these
patients carry a non-inherited autosomal dominant de novo
heterozygous mutation at codon 608 of the LMNA gene encoding
prelamin A. This mutation leads to synthesis of progerin,
a truncated version of the lamin A protein. The aorta and
aortic valves of these patients showed excessive calcification
(Nair et al., 2004; Salamat et al., 2010; Hanumanthappa
et al., 2011). Using the LmnaG609G knock-in mouse model,
which expresses the human HGPS mutation of progerin,
it was shown that LmnaG609G/+ VSMCs exhibit reduced
mitochondrial ATP production along with reduced function
of cytochrome c oxidase (COX), a crucial component of the
mitochondrial electron transport chain (Villa-Bellosta et al.,
2013). These VSMCs also demonstrate a diminished capacity
to synthesize the calcification inhibitor PPi. As ATP is required
for the generation of extracellular PPi by ecto-nucleotide
pyrophosphatase/phosphodiesterase-1 (ENPP1), reduced ATP
availability, due to the dysfunctional electron transport chain
may play a direct role in progressing calcification in HGPS, and
warrants future investigation.
Chronic Kidney Disease
CKD is a gradual loss of kidney function. The reduced kidney
function in CKD patients is concomitant with an increase
in vascular calcification, which is a significant contributor to
cardiovascular mortality in these patients. The mechanisms
which regulate calcification in the CKD vessels have yet to
be fully elucidated. However, mitochondrial dysfunction is
reported within various cells types and tissues during the
progression of the disease. Increased oxidative stress is observed
throughout the progression of CKD (Dounousi et al., 2006).
Additionally, increased skeletal muscle dysfunction is reported
in patients with CKD, mediated through decreased activity
of mitochondrial TCA enzymes including citrate synthase
and hydroxyacyl CoA dehydrogenase (Gamboa et al., 2016).
An association between reduced mitochondria number and
sarcopenia has also been noted in mouse models of CKD
(Tamaki et al., 2014). Furthermore, skeletal muscle from
ESRD patients show swollen mitochondria with increased
levels of BCL2 and adenovirus E1B 19-kDa-interacting protein
3 (BNIP3), an adaptor protein for damaged mitochondria,
suggesting enhanced mitophagy. However, the lysosomes from
these patients show increased accumulation of lipofuscin,
which may reduce their capacity to degrade damaged
mitochondria via mitophagy. In addition, the peripheral
blood mononuclear cells from these patients show reduced
mtDNA copy number and increased lactate accumulation
(Gamboa et al., 2016). Taken together, these data show that
mitochondrial dysfunction in CKD is prominent in skeletal
muscle and PBMCs; however, this needs further investigation
in the blood vessels of CKD patients. Interestingly, there is
an in vivo evidence demonstrating that mitochondria-derived
ROS contributes to microvascular dysfunction in CKD patients
(Kirkman et al., 2018). In addition, oxidative stress induced
vascular calcification and osteoblastic transition of VSMCs
is reported in an adenine diet-based rat model mimicking
human ESRD (Shobeiri et al., 2010; Yamada et al., 2012;
Neven et al., 2015).
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Advanced Glycation End Products
Advanced glycation end products (AGEs) are post-translational
modifications caused by the non-enzymatic binding of free
reducing sugars and reactive carbonyls to proteins or lipids.
AGEs are glycotoxins with pathological significance in diabetes,
aging and several other chronic conditions (Uchiki et al., 2012;
Roca et al., 2014). AGEs accumulate in the extracellular matrix
and within the cells of the vessel wall, contributing to the
development and progression of cardiovascular disease. Elevated
levels of AGEs are typically seen in type-II diabetic patients with
coronary heart disease, and in the macrophages and VSMCs
from the atherosclerotic lesions (Kilhovd et al., 1999). AGE
formation can cause a multitude of receptor-mediated and non-
mediated harmful effects to accelerate the atherosclerotic process
(Basta et al., 2004; Baumann, 2012). Many of these effects
have a role in accelerating the vascular calcification process,
including enhanced synthesis of extracellular matrix components
leading to vascular stiffening (Sims et al., 1996), increased VSMC
proliferation (Zhou et al., 2003) and fibronectin production
(Sakata et al., 2000). AGEs and the receptor for AGEs (RAGE)
generate ROS from mitochondria in the form of free radicals
such as superoxide (O−2 ) and hydrogen peroxide (H2O2) and
ROS. Generation of ROS leads to a vicious cycle of further
ROS production, dysfunctional mitochondria and more AGEs
(Nowotny et al., 2015). Comparably, diabetic RAGE−/− mice are
protected against excess generation of both mitochondrial and
cytosolic superoxide (Tan et al., 2010).
Recently, it has been shown that advanced glycation
products promote both calcification and osteogenic switching of
VSMCs by hypoxia-inducible factor-1-alpha, (HIF-1α)/ pyruvate
dehydrogenase kinase 4, (PDK4) activation (Zhu et al., 2018).
Both HIF-1α/PDK4 contribute toward the metabolic shift to
glycolysis (Lambert et al., 2010; Jeong et al., 2012). Furthermore,
AGEs downregulate p-AMPKα expression and upregulate p-
mTOR expression, thus suppressing autophagy and accelerating
the process of vascular calcification. Treatment with the mTOR
inhibitor rapamycin reverses this effect and reduces osteoblastic
differentiation of VSMCs (Liu et al., 2020). It is interesting to
speculate that blocking AGE associated autophagy could have
an adverse effect on clearance of dysfunctional mitochondria by
mitophagy, which can limit the production of ROS and perhaps
progression of vascular calcification.
Reactive Oxygen Species
Osteochondrogenic transdifferentiation of VSMCs is a key event
during vascular calcification and elevated Pi is the most potent
inducer of this transdifferentiation. Extracellular elevated Ca
adds a synergistic effect to this phenotypic switching (Cui
et al., 2017). In addition to Ca and Pi, there are several other
known factors which contribute to this transdifferentiation,
including bone morphogenetic factors, elevated glucose and
AGEs, dexamethasone, vitamin D3, cytokines, oxidized low
density lipoproteins and hypoxia (Tintut et al., 2000; Dorai
and Sampath, 2001; Razzaque, 2011; Taylor et al., 2011; Alves
et al., 2014; Bessueille et al., 2015; Ceneri et al., 2017; Bao
et al., 2020; Lim et al., 2020). More recently, the role of ROS as
a mediator of osteochondrogenic transdifferentiation has been
recognized (Liberman et al., 2008; Zhao et al., 2011; Byon et al.,
2016). Using an organic compound rose bengal to generate free
radicals such as singlet oxygen and superoxide anions in rats,
Minol et al. demonstrated that ROS induced oxidative stress is
a trigger for smooth muscle cell migration, transdifferentiation
and vascular calcification in atherosclerotic-like focal vascular
degeneration (Minol et al., 2017). Furthermore, hypoxia, which
is commonly seen in calcifying tissues, elevates mitochondrial
ROS formation and osteogenic transdifferentiation in VSMCs
(Chandel et al., 2000). Hypoxic ROS generation is dependent
on mitochondrial electron transport chain complexes II and III
(Chandel et al., 2000; Paddenberg et al., 2003). Studies have
suggested an important role for mitochondrial ROS in the
stabilization of HIF1-α, the key regulator of cellular and systemic
responses to hypoxia (Sato et al., 2005; Hamanaka and Chandel,
2009). Indeed, this effect of mitochondrial ROS is reversed by
N-acetyl cysteine, a ROS scavenger, which downregulates the
expression of HIF-1α, RUNX2 and osteocalcin proteins and
inhibits extracellular matrix calcification (Escobales et al., 2014).
Vascular Aging
Cardiovascular diseases are more prevalent in the aged compared
to the younger population, with aging being a major risk
factor for atherosclerosis. Furthermore, vascular calcification
is a hallmark of age-associated vascular stiffness. Some of
the key changes seen in aging cells include decline in the
function of mitochondrial ETC function, enhanced oxidative
stress and increased senescence (Beckman and Ames, 1998;
Feng et al., 2001; Van Deursen, 2014). It is likely that
oxidative stress and ROS is central to how aging and vascular
calcification connect with each other. Perhaps, HGPS patients
with accelerated aging, elevated ROS, early atherosclerosis and
vascular calcification represent this connection. Indeed, prelamin
A has emerged as a novel biomarker of vascular aging (Ragnauth
et al., 2010), whereby accumulation of this molecule induces
oxidative damage, mitochondrial dysfunction and premature
cell senescence (Sieprath et al., 2015). Prelamin A accumulates
not only in the blood vessels of older individuals but also in
the blood vessels of young CKD patients on dialysis, where it
colocalises with senescent and calcifying VSMCs (Olive et al.,
2010; Ragnauth et al., 2010; Liu et al., 2013).
Mitochondrial dysfunction, increased ROS generation,
increased mtDNA mutation, altered mitochondria fission and
fusion processes and decreased ATP production are mutual to
both aging and calcifying cells in the vessel walls (Chistiakov
et al., 2014; Sobenin et al., 2015). Moreover, aging vascular
cells show reduced expression of antioxidant genes such as
mitochondrial superoxide dismutase 2 (Collins et al., 2009).
Superoxide dismutase 2 binds to oxidative byproducts of
oxidative phosphorylation and plays a crucial role in the defense
against ROS (Collins et al., 2009; Van Raamsdonk and Hekimi,
2012). Tempol, a superoxide dismutase mimetic reduces ROS
production and mitigates aortic stiffness and fibrosis in a
diabetes mellitus mouse model (db/db) (Raaz et al., 2015). It
also down-regulates Runx2 expression (Raaz et al., 2015) a key
positive regulator of vascular calcification. Moreover, diabetes-
accelerated calcification is prevented in rats by the antioxidant
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apocyanin (Brodeur et al., 2014). Use of antioxidant therapy in
attenuating the progression of vascular calcification and vascular
aging has been successful in animal models; however, the results
are less convincing in humans (Fusco et al., 2007; Conti et al.,
2016; Rossman et al., 2018). Interestingly, there is increasing
evidence suggesting that ROS is only a part of the multifaceted
signaling mechanism which works during aging (Doonan et al.,
2008; Cabreiro et al., 2011) and warrants further investigation in
understanding the progression of vascular calcification.
Mitochondrial Dysfunction as a
Consequence of Vascular Calcification
Over recent years, several studies have clearly demonstrated
that VSMCs undergo calcification in response to changes in
extracellular Ca and Pi concentrations. Furthermore, it has been
established that elevated Ca is a more potent stimulus to induce
calcification than elevated Pi, suggesting Ca as a key mediator of
VSMC damage and calcification in pathologies including CKD
and ESRD (Deluca and Engstrom, 1961; Kowaltowski et al.,
1996; Brookes et al., 2004; Oliveira and Kowaltowski, 2004).
Patients with ESRD show high circulating Ca and Pi products and
develop extensive vascular calcification. Persistent Ca overload
induces mitochondrial permeability transition pore opening
(Lemasters et al., 2009), which prompts mitochondrial release
of Ca and ROS into the cytosol, which, in turn, compromises
mitochondrial function. However, the mechanism underpinning
the transportation of Ca and Pi inside the mitochondrial matrix
and cytosol of calcifying cells remain poorly defined. Here
we discuss the actions of Ca and Pi both individually and
synergistically as a cause of mitochondrial dysfunction during
vascular calcification.
Calcium and Phosphate Overload
A number of clinical studies in ESRD patients have shown an
association between elevated serum Ca and Pi levels, increased
risk of myocardial infraction and vascular calcification (Blacher
et al., 2001; Goodman, 2001; Yamada et al., 2007). Although,
the enrichment of Ca crystals within the mitochondrial matrix
during the in vitro vascular calcification process has been
extensively reported (Gonzales and Karnovsky, 1961; Martin and
Matthews, 1970; Sutfin et al., 1971; Kristian et al., 2007; Shroff
et al., 2010; Boonrungsiman et al., 2012). Albeit, it remains to
be investigated whether ESRD patients have elevated cytoplasmic
or mitochondrial Ca or Pi levels. Potentially during vascular
calcification, diffusion of Ca into the mitochondrial matrix could
be a cellular survival mechanism required for prevention of
Ca burden in the cytoplasm strewn from the CaPi-enriched
extracellular surroundings. However, prolonged mitochondrial
Ca overload is the ultimate trigger to initiate apoptosis through
MPTP openings, both of which are observed during late stages of
vascular calcification (Zhu et al., 2019; Chen et al., 2020).
VSMCs calcified under high Pi conditions in vitro show
cytosolic release of cytochrome C, increased caspase 9 and
caspase 3 activity, and apoptosis (Kim et al., 2012; Chang
et al., 2017). In vitro experiments from our laboratory have
shown that VSMCs cultured in high Pi medium show increased
expression of glycolytic enzymes including glucose transporter
1 (Glut1), hexokinase 1 (Hex1), and Pdk4 (Rashdan et al.,
2020). This increase is associated with reduction of ATP-linked
respiration, spare respiratory capacity, and maximal respiration
in VSMCs (Rashdan et al., 2020), suggesting that Pi overload
can block mitochondrial respiration and force the calcifying
VSMCs into glycolysis for energy needs. Mitochondria isolated
from rat brain, liver and heart following exposure to high
concentrations of Pi, show increased ROS production (Oliveira
and Kowaltowski, 2004). These mitochondria display a reduced
mitochondrial matrix pH and altered mitochondrial membrane
potential (Oliveira and Kowaltowski, 2004). It has been shown
that Pi is capable of entering the mitochondrial matrix through a
Pi/OH− exchanger and buffering intramitochondrial pH (Kaplan
et al., 1986). Increased ROS production is also observed in
calcifying aorta of CKD rats fed on a diet rich in Pi, Ca,
and vitamin D (Agharazii et al., 2015). These studies suggest
that high concentrations of Pi is capable of generating ROS,
however, the presence of Ca and Pi together can amplify
ROS generation, causing irreversible mitochondrial damage
(Kowaltowski et al., 1996). Similarly, Ca and Pi synergistically
have a more detrimental effect on mitochondrial function. For
example, the opening of MPTPs in the presence of excess Ca
becomes an irreversible process in the presence of increased
Pi (Kowaltowski et al., 1996). Moreover, a recent study in
cardiac mitochondria has revealed that its the CaPi precipitates
rather than Ca overload which inhibits complex I activity and
oxidative phosphorylation, and the associated reduction in ATP
synthesis (Malyala et al., 2019). Together, these studies suggest
that elevated levels of Ca and Pi togethermay play a crucial role in
inducing mitochondrial damage during the calcification process.
We therefore hypothesize that Ca and Pi overload is a critical
trigger for mitochondrial damage and elevated ROS in patients
with vascular calcification pathologies.
MITOCHONDRIAL QUALITY CONTROL IN
VASCULAR CALCIFICATION
To maintain mitochondrial homeostasis a healthy cell needs
to remove damaged mtDNA and the dysfunctional depolarised
mitochondria. The cell carries out this function by “mitophagy,”
a selective form of autophagy, which degrades these superfluous
and damaged mitochondria and its components. However, the
role of autophagy and mitophagy in vascular calcification has
yet to be fully understood. Detailed reviews on autophagy
and mitophagy can be found elsewhere (Montava-Garriga
and Ganley, 2020; Nishimura and Tooze, 2020; Yim and
Mizushima, 2020). Here we discuss the role of these processes in
mitochondrial quality control during vascular calcification.
Autophagy in Mitochondrial Quality Control
Macroautophagy (autophagy) is the process of removal of
unwanted cellular cytoplasmic contents via double membraned
autophagosomes. This unwanted cytoplasmic content is passed
over to the lysosome for degradation and further recycling.
Recent studies have demonstrated the role of autophagy in
protection against vascular calcification (Dai et al., 2013;
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Shanahan, 2013; Peng et al., 2017; Frauscher et al., 2018;
Phadwal et al., 2020). Furthermore, the role of autophagy
in mitochondrial quality control in VSMCs, specifically
in atherosclerotic plaque development, has been recently
investigated through VSMC-specific deletion of the essential
autophagy gene Atg7 in the Atg7F/F Tagln-Cre+ mouse crossed
with the ApoE−/− mouse model of atherosclerosis (Nahapetyan
et al., 2019). For the first time, this mouse model allowed
interrogation of the consequences of defective autophagy
in the advancement of atherosclerosis. Atg7 is an E1-like
activating enzyme, which facilitates autophagosome formation
and expansion. The Atg7F/F Tagln-Cre+, ApoE−/− mouse
showed significantly increased atherosclerotic lesions with
increased macrophage number and apoptosis. Moreover,
Atg7-deficient VSMCs from these mice revealed excessive
mitochondrial superoxide sensor reactivity. Mitochondria from
these transgenic VSMCs also demonstrated low mitochondrial
membrane potential. In addition, clusters of fragmented
mitochondria were seen present in the close proximity of the
nucleus. These mitochondria also showed reduced respiratory
reserve capacity indicating dysfunctional mitochondria and
impaired clearance (Nahapetyan et al., 2019). Furthermore, these
VSMCs show an accumulation of p62/SQSTM1, PINK1 and
Parkin, indicating impaired mitophagy, a process of selective
degradation of mitochondria via autophagy. This study therefore
suggests that defective autophagy processes in VSMCs result in
dysfunctional mitochondria and contribute to the progression of
atherosclerosis. Similarly, a recent study has demonstrated that
autophagy provides protection against Pi-induced mitochondrial
dysfunction in kidney proximal tubular cells (PTECs) (Fujimura
et al., 2020). Furthermore, proximal tubule-specific autophagy-
deficient mice (Atg5F/F : kidney androgen-regulated protein
mice) fed on a Pi-enriched diet show reduced mitochondrial
respiration and increased oxidative stress, with aggregates
of fragmented and swollen mitochondria observed in the
cytoplasm, suggesting that damaged mitochondria are not
cleared in this mouse model (Fujimura et al., 2020).
Autophagy declines with aging, and conversely enhancing
autophagy has been shown to improve lifespan in yeast, mice,
drosophila and C elegans (Hansen et al., 2018). Furthermore, a
strong link between energy metabolism, autophagy induction
and aging has been established. During cellular aging, energy
metabolism controls autophagic activity via acetyl-CoA
(Eisenberg et al., 2014; Marino et al., 2014). Acetyl-CoA
works as a sentinel metabolite in metabolic regulation. High
nucleocytosolic acetyl-CoA amounts are seen during a “nutrient
rich” state, which leads to its utilization for lipid synthesis
and histone acetylation. However, during “nutrient depletion,”
which also induces autophagy, acetyl-CoA moves toward the
mitochondria for synthesis of ATP and ketone bodies (Eisenberg
et al., 2014; Shi and Tu, 2015). This shuttling of acetyl-CoA
between nucleocytosolic and mitochondrial compartments
holds the key to adapt under metabolic stress. Knockdown of
nucleocytosolic acyl-CoA synthetase 2 (ACS2) leads to a strong
induction of autophagy in chronologically aging yeast, however
the loss of pathways for synthesis of mitochondrial acetyl-CoA
blocks the autophagic flux, suggesting that mitochondrial
acetyl-CoA is crucial for survival during aging. High fat
diet is a risk factor for vascular calcification. Interestingly,
suppression of either acetyl-CoA carboxylase or acyl-CoA
synthetase blocks mineralization in vascular cells (Ting et al.,
2011). Acetyl-CoA carboxylase plays a key role in fatty acid
synthesis via nucleocytosolic acetyl-coenzyme (Pietrocola et al.,
2015). Although the link between suppression of nucleocytosolic
acetyl-CoA, autophagy induction and vascular calcification
remains to be established in vascular cells, it can be speculated
that induced autophagy will have a crucial role in suppressing
high fat diet-induced vascular calcification and lipotoxicity
(Nicoll et al., 2015).
Furthermore, calcifying VSMCs and calcified vessels of
patients with atherosclerosis show increased expression of
PDK4 and phosphorylated pyruvate dehydrogenase complex
(Lee et al., 2015). Phosphate dehydrogenase complex is a
mitochondrial enzyme complex that regulates the conversion of
pyruvate into acetyl-CoA, whereas PDK4 inhibits this complex
by phosphorylating one of its subunits. Under normoxic
conditions, pyruvate produced by glycolysis is transported into
the mitochondria and converted into acetyl-CoA by pyruvate
dehydrogenase complex (Martinez-Reyes and Chandel, 2020).
Acetyl-CoA then enters the TCA cycle. However, under hypoxic
conditions, inhibition of pyruvate dehydrogenase complex
prevents the conversion of pyruvate into acetyl-CoA, leading
to decreased TCA cycle activity in the mitochondria and
increased conversion of pyruvate into lactate in the cytosol also
known as the Warburg effect (Eyassu and Angione, 2017). As
discussed above, this metabolic shift is seen in both the calcified
vessels of atherosclerotic patients (Lee et al., 2015) and calcified
transdifferentiated VSMCs cultured under high Pi conditions
(Rashdan et al., 2020). Recently, it has been demonstrated that
PDK4 drives the metabolic reprogramming of VSMCs toward a
high rate of glycolysis followed by lactic acid generation in the
cytosol (Ma et al., 2020). Inhibition of PDK4 abrogates VSMCs
calcification by inducing lysosomal function and autophagy (Ma
et al., 2020). In conclusion, enhancing autophagy in vascular
calcification pathologies may have a multitude of additional
effects including inhibiting the Warburg effect, suppressing
saturated fatty acid–induced vascular calcification and aiding
cellular survival by clearing away the damaged mitochondria
via mitophagy.
Mitophagy in Mitochondrial Quality Control
Under steady state conditions, dysfunctional mitochondria are
identified by the upregulation of PINK1, which recruits Parkin,
a cytosolic E3 ubiquitin ligase onto the depolarised outer
mitochondrial membrane (Aguirre et al., 2017). Further to
this, PINK1 and Parkin activate ubiquitin and poly-ubiquitin
chains on the depolarised mitochondria, thus triggering their
recognition by autophagy adaptors and receptors including
p62/SQSTM1 and LC3 (Light chain 3), or the proteasome for
degradation (Sarraf et al., 2013). Several outer mitochondrial
membrane proteins such as BCL2 interacting protein 3 (BNIP3),
FUN14 domain- containing protein 1 (FUNDC1), and NIP3-
like protein X (NIX), function as mitophagy receptors by
regulating damaged mitochondrial degradation in response
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to various stimuli. For example, under hypoxia, BNIP3-
induced mitophagy is upregulated in VSMCs following lactate-
induced calcification (Zhang et al., 2008; Zhu et al., 2019).
Furthermore, BNIP3-induced DRP1-mediated mitochondrial
fission is required for mitophagy (Lee et al., 2011). This unique
process of removing damaged depolarised mitochondria is a
crucial safeguardmechanism and an adaptive metabolic response
against accumulation of mtDNA damage, ROS and cell death and
is perhaps functional during vascular calcification. Depolarised
mitochondria (Elmore et al., 2001) and oxidative stress are also
known triggers for mitophagy (Frank et al., 2012). Whilst there is
no direct evidence to show that mitophagy is upregulated during
vascular calcification, it can be speculated that Ca overload
during vascular calcification may trigger a mitophagy response.
A recent study in neuronal cells has shown that Ca
binding controls mitochondrial motility on microtubules via
mitochondrial Rho-GTPase (RHOT1) (Saotome et al., 2008).
Under steady state conditions, RHOT1 mediates mitochondrial
movement on microtubules promoting mitochondrial fusion.
During Ca overload, RHOT1-mediated motility is blocked,
which induces mitochondrial fission via Dynamin 1 Like protein
(DNM1L) (Saotome et al., 2008). This important research
therefore suggests that triggering mitochondrial fission via Ca
overload is required for mitophagy.
Interestingly, pharmaceutical attenuation of vascular
calcification by melatonin is attributed to reduced mitochondrial
fission, increased mitochondrial fusion and mitophagy (Chen
et al., 2020). Furthermore, melatonin increases LC3 and Parkin
expression both in high fat diet-treated ApoE−/− mice and
in oxidized low-density lipoprotein-treated macrophage cells,
suggesting activation of mitophagy (Ma et al., 2018). Melatonin
treatment also inhibits NLRP3 inflammasome activation in
oxidized low-density lipoprotein (ox-LDL) treated macrophages
via activation of mitophagy (Ma et al., 2018).
Conversely, knock down of PINK1 in human dental pulp
stem cells (hDPSCs) results in impaired osteogenesis (Pei et al,
2018). Possibly, mitophagy is underpinning dual roles within
VSMCs by (i) contributing to bone formation via exocytosis
of Ca and Pi-filled mitochondrial-derived vesicles packed in
autolysosomes to the extracellular matrix and (ii) clearing
dysfunctional mitochondria within calcified VSMCs. Further
studies employingApoE−/− mice deficient in PINK1would allow
investigation of the direct role of mitophagy in the development
of vascular calcification and atherosclerosis.
MITOCHONDRIA AND CELL SENESCENCE
IN VASCULAR CALCIFICATION
Cellular senescence along with dysfunctional mitochondria are
hallmarks of aging. Senescence of endothelial cells and VSMCs
is a common feature of atherosclerotic arteries (Minamino et al.,
2002) and ESRD vessels. Vessels from children with ESRD show
increased oxidative DNA damage and increased expression of
senescence markers p16 and p21. VSMCs isolated from these
vessels show accelerated senescence with increased expression
of osteogenic markers and calcification, with a concomitant
increase in levels of the circulating osteogenic senescence-
associated secretory phenotype (SASP) (Sanchis et al., 2019).
Furthermore, human VSMCs cultured in the presence of matrix
vesicles isolated from senescent endothelial HUVECs show
enhanced calcification (Alique et al., 2017). These matrix vesicles
were shown to be enriched with Ca and pro-calcification proteins
including annexins A2 and A6 and BMP2 when compared to
matrix vesicles from young HUVEC cells (Alique et al., 2017). In
a similar study, mitochondrial versican-enriched exosomes from
hyperglycemia-stimulated vascular endothelial cells were able to
induce calcification and senescence in VSMCs cultured under
high glucose conditions (Li et al., 2019), further suggesting a link
between vascular calcification and senescence.
Inflammation is a common occurrence in atherosclerotic
plaque calcification. Inflammatory cytokines including tumor
necrosis factor-α (TNFα) and interleukin 1β (IL-1β) are known
inducers of VSMC phenotype switching and calcification (Tintut
et al., 2000; Ceneri et al., 2017). Interestingly, a 2020 study
has revealed that calcified VSMCs from ESRD patients show
upregulation of IL-1β, activation of senescence (p21) and elevated
osteogenic markers such as bone morphogenetic protein-2
(BMP-2) (Han et al., 2020). Using human VSMCs, the authors
further demonstrated that IL-1β-induced senescence is required
for osteoblastic transdifferentiation in VSMCs. In addition,
senescence-associated secretory phenotype (SASP) along with
the DNA damage response dependent VSMC calcification is
triggered by prelamin A in VSMCs isolated from human aorta
(Liu et al., 2013). Prelamin A (implicated in HGPS) also
induces mitochondrial dysfunction via elevation of ROS in
human fibroblasts (Sieprath et al., 2015). However, mitochondrial
function was not assessed in the VSMCs in these studies.
Together these experiments provide exciting evidence that
the process of vascular calcification is able to induce cellular
senescence and vice versa. However, it is not yet known if
dysfunctional mitochondria are the drivers of VSMC senescence
during the calcification process. Dysregulated mitochondrial
Ca homeostasis, altered mitochondrial membrane potential,
defective oxidative phosphorylation, reduced ATP generation
and increased mitochondrial ROS are the key mitochondrial
changes seen in senescent cells. Importantly, implementation of
the cellular senescence programme specifically requires oxidative
phosphorylation, highlighting mitochondria as the key drivers of
senescence (Kaplon et al., 2013; Herranz and Gil, 2016). It has
been shown that the use of senolytic compounds such asmitocans
that target cells with increasedmitochondrial potential selectively
kills senescent cells by altering their oxidative phosphorylation
levels and mitochondrial membrane potential (Hubackova
et al., 2019). Furthermore, elamipretide, a mitochondria-targeted
peptide, can partly alleviate kidney cellular senescence in porcine
atherosclerotic renal artery stenosis by alleviating oxidative stress,
and restoring mitochondrial biogenesis and mitophagy (Kim
et al., 2019).
Recent elegant studies in fibroblasts have demonstrated that
mitochondria underpin pro-aging characteristics of the senescent
phenotype (Correia-Melo et al., 2016). Cellular senescence
features including up-regulation of senescence-associated
secretory phenotype (SASP), p21 and P16, are observed in a novel
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parkin-mediatedmitochondrial clearancemodel (Narendra et al.,
2008). Comparable studies in VSMCs would greatly advance
our understanding of the role of mitochondria-derived cellular
senescence in vascular calcification.
KEY MITOCHONDRIAL TARGETS IN
VASCULAR CALCIFICATION
Current literature suggests that ROS is central to mitochondrial
dysfunction during the progression of vascular calcification.
Several natural dietary, natural non-dietary and synthetic
antioxidant compounds, which can scavenge ROS, are being
tested for therapeutic efficacy against vascular calcification in
clinical trials (Roman-Garcia et al., 2011; Kim et al., 2012; Chang
et al., 2017; Chao et al., 2019).
ROS generation is tightly coupled to mitochondrial
ultrastructure changes of fusion and fission. Mitochondrial
fusion/fission is linked with several physiological indicators
of mitochondrial dysfunction, including loss of mitochondrial
membrane potential, decreased respiration and oxidative
phosphorylation, metabolic shift toward glycolysis, and
accelerated mitochondrial ROS. Drp1 is a key regulator of
mitochondrial fission (Twig et al., 2008), and is seen enriched
in calcified regions of human carotid arteries (Rogers et al.,
2017). In vitro studies suggest that DRP1 inhibition can
attenuate mitochondrial damage both in calcifying VSMCs
and in valve interstitial cells, concomitantly reducing vascular
calcification (Rogers et al., 2017). Moreover, compounds such
as metformin and melatonin abrogate vascular calcification
by inhibiting DRP1-induced mitochondrial fission (Rogers
et al., 2017; Chen et al., 2020). Metformin also suppresses
diabetes-accelerated atherosclerosis via the inhibition of
Drp1-mediated mitochondrial fission (Wang et al., 2017). It
is interesting to speculate a three-way effect of metformin on
mitochondrial function in diabetes-accelerated atherosclerosis,
(1) by inhibiting redox shuttle enzyme mitochondrial
glycerophosphate dehydrogenase and thus blocking glucose
generation by gluconeogenesis, (2) by attenuating mitochondrial
ROS generation by inhibiting mitochondrial complex I, and (3)
by inhibition of DRP1-mediated mitochondrial fission (Madiraju
et al., 2014; Hur and Lee, 2015).
Inhibition of DRP-1 mediated mitochondrial fission also
prevents MPTP opening and cell death in HL-1 cells, a
cardiac-derived cell line (Ong et al., 2010). Mitochondrial
division inhibitor 1 (mdivi-1), a quinazonilone derivative
and a DRP1 inhibitor, is able to attenuate oxidative stress-
mediated calcification of murine VSMCs by reducing TNAP
expression and calcified collagenous matrix production (Rogers
et al., 2017). We hypothesize that DRP1 is a key regulator of
mitochondrial damage in vascular calcification and underlying
pathologies. We further hypothesize that ROS generated during
calcifciation process leads to post-translational modifications
of DRP1, which may hold the key to its regulation in vascular
calcification pathologies. Indeed, several such post-translational
modifications of DRP1 has been reported in various cell
types. For example, DRP1 acetylation and s-nitrosylation
enhances mitochondrial fragmentation in cardiomyocytes
and neurons respectively, whereas oxidoreduction of Drp1
protects against mitochondrial fission and ROS generation in
endothelial cells (Cho et al., 2009; Kim et al., 2018; Hu et al.,
2020).
Hypoxia-inducible factor-1 (HIF-1) is a crucial regulator
of vascular calcification. Increase in ROS levels stabilize and
activate HIF-1α, which triggers VSMC transdifferentiation
and calcification (Patten et al., 2010; Mokas et al., 2016).
Osteocalcin, a bone derived hormone promotes phenotype
switching in VSMCs and enhances their glucose metabolism
and calcification through a HIF-1α-dependent mechanism
(Idelevich et al., 2011). Furthermore, an increased nuclear
staining for HIF-1α is observed in a CKD rat model
(CKD induced by renal mass reduction) fed on a Ca and
Pi-enriched diet (Mokas et al., 2016). Increased HIF-1α
expression is accompanied by increased expression of HIF-
1 regulated genes, such as vascular endothelial growth factor
A (VEGFA) and GLUT-1, and reduced expression of VSMC
specific markers including actin alpha 2 (ACTA2), Calponin
1 (CNN1), Smooth Muscle Protein 22 (SM22), and myosin
heavy chain 11 (MYH11), triggering VSMC transdifferentiation.
Furthermore, in calcified VSMCs, elevated Pi levels activate
and stabilize HIF-1 independently of oxygen levels by targeting
its oxygen-dependent degradation via the ubiquitin proteasome
system (Mokas et al., 2016). Exposure of these VSMCs to a
mitochondrial targeted antioxidant (SkQ1) and a mitochondrial
complex III inhibitor (stigmatellin) blocks this Pi-induced HIF-
1 upregulation and calcification (Mokas et al., 2016); suggesting
mitochondrial ROS is required for HIF-1 stabilization in Pi-
treated VSMCs.
In conclusion, mitochondrial ROS, DRP1, and HIF-1 are
highly attractive markers for vascular calcification pathology
and offer novel therapeutic targets to improve mitochondrial
function during vascular calcification. Furthermore, targeting
inhibitors including Fetuin-A, (to reduce Ca Pi precipitation)
and, ENPP1, (to reduce Pi overload) could provide an
upstream approach to restoring mitochondrial homeostasis in
vascular calcification.
CONCLUDING REMARKS
This is a renaissance period for mitochondrial research
in vascular calcification. Mitochondrial dysfunction seen in
vascular calcification pathologies is strongly associated with
mineral dysregulation, ROS generation, phenotypic switching
of VSMCs and metabolic shift from oxidative phosphorylation
to glycolysis. It would be beneficial to investigate the sequence
of mitochondrial dysfunction in a spatiotemporal manner in
vascular calcification models.
Whilst Ca and Pi overload during vascular calcification is
a likely cause of mitochondrial dysfunction, the mechanisms
of Ca and Pi transport to the mitochondrial matrix from
the extracellular matrix remain elusive. Moreover, investigating
mitochondrial dysfunction during the progression of vascular
calcification in mouse models lacking key calcification regulators
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e.g., Runx2 (Lin et al., 2015) and Enpp1 (Li et al., 2013; Huesa
et al., 2015) will further define the mechanisms of mitochondrial
dysfunction during this process. Additionally, the employment
of fluorescent tags fused to mitochondria such as mitoQC
(McWilliams et al., 2016), Keima (Sun et al., 2015) or mitotimer
(Hernandez et al., 2013) in vascular calcification murine
models including mice with ApoE ablation or CKD induction
will allow the investigation of mitochondrial architecture,
biogenesis and turnover via mitophagy during the progression
of calcification.
In conclusion, maintaining mitochondrial homeostasis is
crucial to protect cells against vascular calcification. Future
therapeutic strategies targeted toward molecular regulation of
mitochondrial ROS, DRP-1 and HIF-1 could be successful tools
in the prevention of vascular calcification pathology and warrant
further investigation.
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